What is Tirzepatide?
Tirzepatide is a first-in-class dual GIP and GLP-1 receptor agonist developed to improve blood sugar control and metabolic health. It is the active compound in the FDA-approved drugs Zepbound® (weight loss) and Mounjaro® (type 2 diabetes).
Reported Benefits from Research & Clinical Trials
- Weight Loss: Average 15%–21% total body weight reduction
- Improved Glycemic Control: Lower fasting glucose, improved HbA1c
- Reduced Insulin Resistance: Enhanced insulin sensitivity and beta-cell function
- Cardiovascular Support: Reduced systolic blood pressure and LDL cholesterol
- Anti-inflammatory Effects: Reduction in C-reactive protein (CRP)
- Liver Support: Lower ALT/AST in NAFLD patients
- Appetite Suppression: Promotes satiety, delays gastric emptying
- Improved Lipid Profile: Lower triglycerides and dense LDL particles
Source: Drugs.com Clinical Comparison
How It Works
Tirzepatide mimics two hormones: GIP and GLP-1. These enhance insulin release, reduce glucagon levels, slow gastric emptying, and reduce appetite. Together, they regulate metabolism and support weight and blood sugar management.
Typical Dosing Schedule in Research Contexts
In many published trials and anecdotal research scenarios, Tirzepatide is introduced gradually to allow the subject system to adapt to gastrointestinal effects:
- Weeks 1–4: 2.5mg once per week
- Weeks 5–8: 5mg once per week
- Weeks 9–12: 7.5mg once per week
- Weeks 13–16: 10mg once per week
- Optional: Some protocols escalate to 12.5mg or 15mg as tolerated
This information is based on public sources and not a recommendation for any use. Our products are not for human consumption.
Branded Versions & Our Advantage
- Zepbound®: Approved for chronic weight management (Eli Lilly)
- Mounjaro®: Approved for type 2 diabetes (Eli Lilly)
- Peppy Health NJ: Offers the same high-purity Tirzepatide for research use only at a fraction of the cost
Visual Transformation Stories (Anecdotal Research)
These images are from publicly shared Reddit users documenting Tirzepatide research outcomes:
